Clinical meaning
Type 2 diabetes mellitus results from the interplay between insulin resistance in target tissues and progressive pancreatic beta-cell dysfunction, a concept described as the 'ominous octet' of pathophysiological defects. Insulin resistance: In normal physiology, insulin binds to the insulin receptor (a tyrosine kinase receptor) on target cells, triggering autophosphorylation and activation of the IRS-1/PI3K/Akt signaling cascade, which promotes GLUT4 transporter translocation to the cell membrane for glucose uptake (primarily in skeletal muscle and adipose tissue), stimulates glycogen synthesis in liver and muscle, and suppresses hepatic gluconeogenesis. In insulin resistance, this signaling pathway is impaired at multiple levels: (1) serine phosphorylation of IRS-1 (instead of tyrosine phosphorylation) by inflammatory kinases (JNK, IKK-beta) inactivates the insulin signaling cascade; (2) excess free fatty acids from visceral adipose lipolysis activate protein kinase C (PKC) in muscle and liver, further impairing insulin receptor signaling; (3) adipose tissue dysfunction shifts adipokine secretion toward pro-inflammatory mediators (TNF-alpha, IL-6, resistin) and away from protective adiponectin, creating a chronic low-grade inflammatory state that perpetuates insulin resistance. The result is decreased glucose uptake in skeletal muscle (accounting for ~75% of postprandial glucose disposal), increased hepatic glucose production (from unrestrained gluconeogenesis and glycogenolysis despite hyperinsulinemia), and increased lipolysis (further elevating free fatty acids -- lipotoxicity). Beta-cell failure: Initially, beta cells compensate for peripheral insulin resistance by increasing insulin secretion (compensatory hyperinsulinemia). Over time, the beta cells become exhausted and fail through several mechanisms: (1) glucotoxicity -- chronic hyperglycemia directly damages beta cells through oxidative stress and advanced glycation end-product (AGE) formation; (2) lipotoxicity -- elevated free fatty acids impair insulin gene expression and promote beta-cell apoptosis; (3) amyloid deposition -- islet amyloid polypeptide (IAPP/amylin), co-secreted with insulin, forms toxic amyloid fibrils that destroy beta cells in T2DM; (4) loss of first-phase insulin secretion -- the rapid insulin release from preformed granules within the first 10-30 minutes after a glucose load is the FIRST defect lost in T2DM, making postprandial hyperglycemia the earliest manifestation. Additional defects include alpha-cell dysfunction (excess glucagon secretion that is not appropriately suppressed by hyperglycemia, contributing to hepatic glucose overproduction), decreased incretin effect (GLP-1 and GIP hormones from the gut that normally augment glucose-dependent insulin secretion are reduced or their receptors are downregulated), increased renal glucose reabsorption (SGLT2 transporter upregulation in the proximal tubule raises the glucose reabsorption threshold, maintaining hyperglycemia), and central nervous system insulin resistance (impaired hypothalamic appetite regulation contributing to obesity).